Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic etiology ,which has number of different clinical forms. Alternative natural or herbal origine drugs with antioxidant and anti-inflammatory properties have been used individually or in combination with systemic corticosteroids in order to decrease adverse drug reactions.

This study was conducted to evaluate the effect of quercetin on treatment of erosive -atrophic lesions of oral lichen planus (OLP).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Purslane in Treatment of Oral Lichen Planus

NCT00746772

Lichen Planus, Oral

COMPLETED PHASE2

Efficacy of Green Tea Buccal Tablets in Oral Lichen Planus

NCT03415165

Oral Lichen Planus

UNKNOWN EARLY_PHASE1

Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus

NCT04652739

Erosive Lichen Planus

COMPLETED PHASE2/PHASE3

The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients

NCT03877679

Oral Lichen Planus

UNKNOWN PHASE1

Treatmant of Oral Lichen Planus With Lycopene

NCT00656214

Lichen Planus, Oral

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrophic Oral Lichen Planus Erosive Oral Lichen Planus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

quercetin

quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action

Group Type ACTIVE_COMPARATOR

Quercetin

Intervention Type DRUG

The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth

placebo

placebo capsul is produced with lactose for using in placebo/ control group.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

The patient is directed to use placebo capsule two times a day, ,until the one mouth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

The patient is directed to use placebo capsule two times a day, ,until the one mouth

Intervention Type DRUG

Quercetin

The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmation of clinical diagnosis of Atrophic and erosive lichen planus by histological examination
* two weeks wash out periods after the last treatment
* having the experience of atrophic and erosive lesion greater than 1 cm having the experience of pain and burning greater than 3.5 in VAS Score

Exclusion Criteria

* confirmation of dysplasia and malignancy in histologic examination
* confirmation of lichenoid reaction in histologic examination
* pregnancy and breast feeding
* using fluorokinolon and cyclosporin which interact with quercetin

Minimum Eligible Age

12 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No